secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001651308-25-000151
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines promotes Lai Wang to President, Global Head of R&D effective Jan 1, 2026
--------------------------------------------------------------------------------

- Dr. Lai Wang appointed President, Global Head of R&D, overseeing R&D, business development, and alliance management.
- Promotion effective January 1, 2026; annual salary $750,000 with target bonus of 75% of base salary.
- One-time RSU equity award of $10M vesting in equal annual installments over four years.
- Dr. Wang had served as Global Head of R&D since April 2021 and joined the company in 2011.
- No family relationships or material interests in transactions with directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/0001651308-25-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/bgne-20251217.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer